Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 15/20 | 0.57 |
| ▸ | JAK1 | P23458 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL31096018 | 1.00 | TYK2 (0.57) | TYK2JAK1KCNH2STAT3AXL | |
| SCHEMBL25671619 | 0.92 | TYK2 (0.56) | TYK2JAK1KCNH2STAT3AXL | |
| SCHEMBL31095902 | 0.92 | TYK2 (0.56) | TYK2JAK1KCNH2STAT3AXL | |
| Lithium SCHEMBL31017478 | 0.91 | TYK2 (0.56) | TYK2JAK1KCNH2STAT3AXL | |
| SCHEMBL25749407 | 0.91 | TYK2 (0.65) | TYK2JAK1KCNH2STAT3JAK2 | |
| Lithium Ion SCHEMBL31096181 | 0.90 | AXL (0.51) | TYK2JAK1KCNH2STAT3AXL | |
| Lithium Ion SCHEMBL27199669 | 0.90 | AXL (0.51) | TYK2JAK1KCNH2STAT3AXL | |
| SCHEMBL30465857 | 0.89 | TYK2 (0.58) | TYK2JAK1KCNH2STAT3AXL | |
| SCHEMBL29883117 | 0.83 | TYK2 (0.77) | TYK2JAK1KCNH2STAT3JAK2 | |
| SCHEMBL29232108 | 0.83 | TYK2 (0.77) | TYK2JAK1KCNH2STAT3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885KCNH2 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.